JAMA: Moderna's mRNA vaccine has fewer breakthrough infections, fewer hospitalizations than Pfizer

At the end of 2020, it took only one year for Pfizer/BioNTech and Moderna to develop a new crown mRNA vaccine, which was approved for marketing

With the continuous emergence and large-scale spread of new mutants of the new coronavirus, the protective effect of the vaccines developed against the original strains began to decline, and some people who had received two doses of mRNA vaccines were still infected with the new coronavirus, which is the so-called " breakthrough ".

On January 20, 2022, Rong Xu of Case Western Reserve University and others published a paper entitled: Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Research paper on Delta-Predominant Period

The paper compared breakthrough infections, hospitalizations, and deaths during the delta mutant epidemic between two mRNA vaccines from Pfizer/BioNTech and Moderna, respectively

Rong Xu, who led the study, is a professor of bioinformatics at Case Western Reserve University School of Medicine and director of the Center for Artificial Intelligence Drug Discovery

The statistics are based on a breakthrough infection of the new crown between July 2021 and November 2021, when Delta accounted for almost all cases

Statistical results show that compared with Pfizer/BioNTech's mRNA vaccine, the monthly breakthrough infection rate of people vaccinated with Moderna's mRNA is lower.

These data suggest that the two mRNA vaccines, despite their differences in preventing breakthrough infections, both have good protection against severe disease

With the rapid spread of Omicron, it is necessary to further evaluate the protective effect of the booster needle, and it is also necessary to develop a vaccine against Omicron

Original source:

Lindsey Wang, et al.